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neoplasms3,4 that were excluded from the analy-
sis performed by Cochand-Priollet et al. Most 
important, blinded, prospective, large-scale, mul-
ticenter clinical trials to investigate these mark-
ers are lacking. High-quality investigations are 
critical for any molecular analysis before find-
ings can be translated into clinical practice. 
Lastly, we note an error in the letter from Pusz-
taszeri: the sensitivity of the gene-expression 
classifier was 92%, not 52%.
We agree with Dominguez that both negative 
and positive predictive values are influenced by 
the prevalence of cancer in a population. It is 
reasonable to characterize the performance of a 
diagnostic test with negative likelihood ratios, 
which is independent of the disease prevalence. 
However, computation of the negative likelihood 
ratio is accurate only when all other characteris-
tics of the cohort are the same — a condition 
that is rare in the clinical setting.5 Our valida-
tion study included many sites and ethnic groups 
across the United States, including academic and 
community practices, patients ranging in age 
from 22 to 85 years, various nodule sizes, and 
many methods of fine-needle aspiration biopsy. 
We therefore believe our results are applicable 
for broad routine use.
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Tofacitinib in Active Ulcerative Colitis
To the Editor: Sandborn et al. (Aug. 16 issue)1 
report that tofacitinib has efficacy in the treat-
ment of ulcerative colitis. The authors note that 
Janus kinase (JAK) inhibitors JAK1 and JAK3 are 
surprisingly ineffective in the treatment of 
Crohn’s disease.2 In Crohn’s disease, the major 
cytokines arise from the differentiation of two 
subtypes of CD4+ T cells — Th1 and Th17 — 
whereas in ulcerative colitis a Th2-like differen-
tiation process seems to be involved. Several re-
cent reports on different experimental models 
seem to indicate that JAK inhibitors such as to-
facitinib suppress Th2 but potentiate Th1 and 
Th17 responses. For example, a low dose of to-
facitinib accelerates the onset of experimental 
autoimmune encephalomyelitis by potentiating 
Th17 differentiation.3 JAK inhibitors such as to-
facitinib and pyridone 6, a pan-JAK inhibitor, 
also strongly reduce Th2 response and potentiate 
Th1 and Th17 responses in different diseases.4 
Moreover, tofacitinib has been also described as 
inhibiting interleukin-4–dependent Th2 cell dif-
ferentiation in both murine and human T cells.5
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To the Editor: In the evaluation of tofacitinib in 
the treatment of active ulcerative colitis by Sand-
born et al., the population selection was hetero-
geneous in terms of previous treatment received, 
with the majority of patients (52 to 70%) having 
received mesalamine, 27 to 58% having received 
glucocorticoids, and 37 to 42% having received 
immunosuppressants; none of these treatments 
had been effective. No mention is made of gluco-
corticoid dependence or resistance.
In clinical practice, when patients with mod-
erate-to-severe ulcerative colitis show no improve-
ment in response to treatment with mesalamine 
or a dosage of glucocorticoids lower than 30 mg 
per day, guidelines indicate that the dosage of 
glucocorticoids may be increased to 0.75 to 1.0 mg 
per kilogram of body weight, a level at which 
there is an acceptable rate of remission.1 In the 
trial conducted by Sandborn et al., the remission 
rate was 48% in patients receiving 10 mg of 
tofacitinib twice daily, a result that is not im-
pressive for patients in whom treatment with 
mesalamine or less than 30 mg per day of gluco-
corticoids was not effective. Glucocorticoid with-
drawal was not considered as an end point — 
another weakness of this study. In conclusion, 
we do not find this new drug to be a promising 
novel therapeutic since the trial presented did 
not give clinicians a clear indication of the cir-
cumstances in which it should be used.
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The Authors Reply: The effects of tofacitinib in 
patients with ulcerative colitis that we reported 
were from a phase 2 study. This study was de-
signed to provide proof-of-concept for tofacitinib 
as an induction therapy and to elucidate the safe-
ty and efficacy profiles of various doses of tofaci-
tinib to take forward for further investigation in 
larger phase 3 studies; these goals were achieved. 
On the basis of the study results, a phase 3 clini-
cal program has been initiated, consisting of two 
studies investigating the use of tofacitinib as an 
induction therapy (ClinicalTrials.gov numbers, 
NCT01465763 and NCT01458951), a third study 
in which tofacitinib is used as a maintenance 
therapy (NCT01458574), and an open-label, long-
term extension study (NCT01470612). This pro-
gram should provide data that will allow clini-
cians to make more informed decisions about 
the potential use of tofacitinib in practice, in-
cluding the specific patient populations likely to 
benefit from treatment, the effects of tofacitinib 
when used as maintenance therapy, and the ef-
fects when patients are spared from the use of 
glucocorticoids — information sought by Cot-
tone et al.
The effects of tofacitinib in patients with 
Crohn’s disease were studied in a separate phase 
2a study.1 Although there was no evidence of 
significant clinical efficacy, dose-dependent re-
ductions in levels of C-reactive protein and sig-
nificant reductions in fecal levels of calprotectin 
were observed in the group receiving 15 mg of 
tofacitinib twice a day. We acknowledge the pos-
sibility raised by Paul and Roblin that mecha-
nistic differences in the pathophysiologies of 
ulcerative colitis and Crohn’s disease contrib-
uted to the different outcomes seen in each study. 
However, neither the precise role played by JAK 
inhibition in the pathogenesis of inflammatory 
bowel disease nor the disease-specific differ-
ences in its activity is well understood, and it is 
also possible that the lack of observed clinical 
efficacy in the trial addressing Crohn’s disease 
can be attributed to certain features of study 
design. An additional Phase 2b clinical pro-
gram, including three studies (NCT01393626, 
NCT01393899, and NCT01470599), has been 
initiated to further investigate whether the 
positive biomarker signals observed with to-
facitinib in the previous study can be translated 
into clinical efficacy for patients with Crohn’s 
disease.
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Effect of HIV-2 Infection on HIV-1 Disease Progression
To the Editor: Esbjörnsson and colleagues (July 
19 issue)1 conclude that infection with human im-
munodeficiency virus type 2 (HIV-2) attenuates 
the course of HIV-1 infection. Their report raises 
three issues. First, in Guinea-Bissau, up to 30% 
of persons infected with both HIV-1 and HIV-2 
have coinfection with human T-cell lymphotropic 
virus type 1 (HTLV-1),2 a circumstance that leads 
to an increased percentage of CD4+ T cells.3 The 
authors did not control for coinfection with 
HTLV-1, a condition that may well have contrib-
uted to the high percentage of CD4+ T cells 
among persons with dual HIV infection. Second, 
despite the study’s long follow-up time, the au-
thors did not treat age as a time-dependent vari-
able in the Cox regression analyses; failure to have 
done so may have led to the appearance of a re-
duction in the rate of disease progression. In a 
recently published survival analysis (including 70 
participants with dual HIV infection who were 
followed for 20 years) in which age was treated as 
a time-dependent variable, no differences in mor-
tality were observed between participants with 
HIV-1 infection only and those with dual infec-
tion.4 Finally, none of six studies comparing mor-
tality rates between participants with HIV-1 infec-
tion only and participants with dual infection 
reported lower mortality among participants with 
dual infection (see the figure published with the 
full text of this letter at NEJM.org)5; the findings 
of Esbjörnsson and colleagues seem to be at odds 
with the findings in these studies and with the 
fact that HIV-2 infection does not affect HIV-1 
viral load in persons with dual infection.5
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To the Editor: Esbjörnsson and colleagues re-
port that HIV-2 infection can favorably modulate 
the course of early HIV-1 infection, with reduced 
HIV-1 genetic diversity serving as a marker for 
delayed disease progression. Unraveling the 
mechanism behind these findings could help de-
fine immune correlates of protection from HIV-1 
disease. In our view, preexisting HIV-2-specific 
T-cell responses in the study participants are the 
most likely explanation for both observations. 
We have previously shown that the presence of 
high-magnitude Gag-specific T-cell responses in 
persons with HIV-2 infection is inversely corre-
lated with HIV-2 viremia.1 These responses are 
more polyfunctional than HIV-1-specific respons-
es.2 HIV-1 and HIV-2 Gag have a shared sequence 
identity of 60%. Recognition of naturally pro-
cessed HIV-1 Gag antigens for alleles such as 
HLA-B35 and HLA-B58 (both of which are com-
mon in Guinea-Bissau) by HIV-2-specific cyto-
toxic T-lymphocytes (CTLs) has been reported.3,4 
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